Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Pedersen, Jannie ^a,e   Jensen, Tanja B ^a,e   Carlsen, Thomas H R ^a,e   Schønning, Kristian ^a   Christensen, Peer Brehm ^b   Laursen, Alex Lund ^c   Krarup, Henrik ^d   Bukh, Jens ^a,e   Weis, Nina ^a,e  

^a Mental Health Center Glostrup   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS ENVELOPE PROTEIN;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE CLUSTER; GENOTYPE; HEPATITIS C; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; TREATMENT DURATION; VIRUS CULTURE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; CULTURE TECHNIQUES; DNA, RECOMBINANT; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MUTATION; RIBAVIRIN; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS;

EID: 84877125433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062674     Document Type: Article

References (54)

1. Lavanchy D, (2009) The global burden of hepatitis C. Liver Int. 29Suppl 1: 74-81.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
3. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, et al. (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 38: 645-652.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
5. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, et al. (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024.
6. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
7. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, et al. (2012) Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 56: 78-84.
8. Askarieh G, Alsio A, Pugnale P, Negro F, Ferrari C, et al. (2010) Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 51: 1523-1530.
9. Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, et al. (2011) Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53: 14-22.
10. Salmeron J, De Rueda PM, Ruiz-Extremera A, Casado J, Huertas C, et al. (2006) Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C. Dig Dis Sci. 51: 960-967.
11. Clausen LN, Weis N, Astvad K, Schønning K, Fenger M, et al. (2011) Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 18: e66-e74.
12. Hansen N, Obel N, Christensen PB, Kjaer M, Laursen AL, et al. (2011) Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study. BMC Infect Dis 11: 177.
13. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
14. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, et al. (2009) Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49: 364-377.
15. Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, et al. (2008) Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J Infect Dis 198: 1756-1765.
16. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, et al. (2008) Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc Natl Acad Sci U S A 105: 997-1002.
17. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, et al. (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 103: 7408-7413.
18. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
19. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, et al. (2011) Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J Virol 85: 2891-2906.
20. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, et al. (2007) Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133: 1614-1626.
21. Yi M, Ma Y, Yates J, Lemon SM, (2007) Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol 81: 629-638.
22. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, et al. (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191: 1499-1512.
23. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, et al. (1996) Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98: 706-714.
24. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, et al. (2011) In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 53: 755-762.
25. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101: 10149-10154.
26. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, et al. (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 104: 6025-6030.
27. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, et al. (2012) Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 205: 763-771.
28. Rehermann B, (2009) Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 119: 1745-1754.
29. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, et al. (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132: 667-678.
30. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, et al. (2004) Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127: 1724-1732.
31. Boo I, Fischer AE, Johnson D, Chin R, Giourouki M, et al. (2007) Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin. J Clin Virol 39: 288-294.
32. Sasayama M, Deng L, Kim SR, Ide Y, Shoji I, et al. (2010) Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin. Kobe J Med Sci 56: E60-E66.
33. Christensen PB, Krarup HB, Moller A, Laursen AL, Kjaer MS, et al. (2007) Liver biopsy performance and histological findings among patients with chronic viral hepatitis: a Danish database study. Scand J Infect Dis 39: 245-249.
34. Hansen N, Obel N, Christensen PB, Krarup H, Laursen AL, et al. (2009) Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat 16: 659-665.
35. Corbet S, Bukh J, Heinsen A, Fomsgaard A, (2003) Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol 41: 1091-1100.
36. Ramirez S, Perez-Del-Pulgar S, Carrion JA, Coto-Llerena M, Mensa L, et al. (2010) Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. J Gen Virol 91: 1183-1188.
37. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, et al. (2010) Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 84: 5277-5293.
38. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, et al. (2011) Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 85: 2224-2234.
39. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, et al. (2005) An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79: 8217-8229.
40. Meunier JC, Engle RE, Faulk K, Zhao M, Bartosch B, et al. (2005) Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102: 4560-4565.
41. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, et al. (2013) Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus e2 glycoprotein. J Virol 87: 37-51.
42. Keck ZY, Xia J, Wang Y, Wang W, Krey T, et al. (2012) Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog 8: e1002653.
43. Kong L, Giang E, Robbins JB, Stanfield RL, Burton DR, et al. (2012) Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A 109: 9499-9504.
44. Gerotto M, Dal PF, Loffreda S, Bianchi FB, Alberti A, et al. (2001) A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2. Blood 98: 2657-2663.
45. Hohne M, Schreier E, Roggendorf M, (1994) Sequence variability in the env-coding region of hepatitis C virus isolated from patients infected during a single source outbreak. Arch Virol 137: 25-34.
46. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, et al. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A 109: 6205-6210.
47. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, et al. (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol 81: 8101-8111.
48. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14: 25-27.
49. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A 106: 7537-7541.
50. Fofana I, Fafi-Kremer S, Carolla P, Fauvelle C, Zahid MN, et al. (2012) Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies. Gastroenterology 143: 223-233.
51. Farci P, Munoz SJ, Shimoda A, Govindarajan S, Wong DC, et al. (1999) Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee. J Infect Dis 179: 1007-1011.
52. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, et al. (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277: 570-574.
53. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von OJ, et al. (2001) Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34: 809-816.
54. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, et al. (2010) Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 84: 5067-5077.